Navigation Links
Idenix Announces Data Presentations at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:3/7/2011

CAMBRIDGE, Mass., March 7, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that two abstracts have been accepted for presentation at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL, March 30- April 3, 2011 in Berlin, Germany).  Full abstracts can now be viewed at the EASL website at www.easl.eu.

The accepted abstracts are as follows:

  • Standring, et al, "Idenix NS5A HCV Replication Inhibitors with Low Picomolar, Pan-Genotypic in vitro Antiviral Activity" will be presented in a poster session beginning on Friday,  April 1.

  • Standring, et al, "No Resistance to IDX184 Was Detected in 3-day and 14-day Clinical Studies of IDX184 in Genotype 1-Infected HCV Subjects" will be presented in a poster session on Saturday, April 2.

  • About IdenixIdenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, please refer to www.idenix.com.

    Forward-looking Statements  This press release contains "forward-looking statements" for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, including but not limited to the statements regarding the company's future business and financial performance. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "expect," "plans," "anticipates," "will," and similar expressions are also intended to identify forward-looking statements, as are expressed or implied statements with respect to the company's potential pipeline candidates, including any expressed or implied statements regarding the efficacy and safety of our drug candidates, the likelihood and success of any future clinical trials involving our drug candidates. Actual results may differ materially from those indicated by such forward-looking statements as a result of risks and uncertainties, including but not limited to the following: there can be no guarantees that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization; management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaborations with Novartis Pharma AG and GlaxoSmithKline/ViiV Healthcare; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. These and other risks which may impact management's expectations are described in greater detail under the heading "Risk Factors" in  the company's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission (SEC) and in any subsequent periodic or current report that the company files with the SEC.

    All forward-looking statements reflect the company's estimates only as of the date of this release  (unless another date is indicated) and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. While Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if the company's estimates change.Idenix Pharmaceuticals Contact:Kelly Barry (617) 995-9033 (media)Eric Hoffman (617) 224-4485 (investors)
    '/>"/>

    SOURCE Idenix Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
    2. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
    3. Idenix to Host Conference Call Discussing Fourth Quarter and Year End 2010 Financial Results
    4. Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results
    5. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
    6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
    7. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
    8. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
    9. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
    10. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
    11. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/22/2017)... 2017 Summary Provides understanding and ... and agreements entered into by the worlds leading healthcare ... Description The Global Non-Small Cell Lung Cancer Partnering ... access to partnering deals and agreements entered into by ... in partnering deals - Top deals by value ...
    (Date:2/22/2017)... PUNE, India , February 22, 2017 ... titled, "Automated Radio Synthesis Modules Market: Global Opportunity Analysis and ... market was worth $20 million in 2015 and projected to ... 6.6% from 2016 to 2022. North America ... market revenues and unit volumes, whereas Asia-Pacific ...
    (Date:2/22/2017)... February 22, 2017 A research report by ... America and the continuously changing landscape of the legal ... in the North America , a 30% increase ... to $21.6 billion by the year 2021 representing a 26 percent ... the United States and Canada ...
    Breaking Medicine Technology:
    (Date:2/22/2017)... ... 2017 , ... Forty-five percent of American respondents feel that ... or friends have also commented about their poor hearing. However, only 13 percent ... reason, suggested by 89 percent of American respondents, is that they don’t want ...
    (Date:2/22/2017)... ... 22, 2017 , ... Pet obesity in the U.S. continued to steadily increase ... Association for Pet Obesity Prevention (APOP). During the ninth annual survey, APOP also found ... benefits of corn and grains, value of raw and organic diets, and the best ...
    (Date:2/22/2017)... ... February 22, 2017 , ... BrightStar Care Charleston , a home ... University of South Carolina (MUSC) Center on Aging’s Senior Expo on Thursday, March ... Aging is a tremendous resource in our community. We are thrilled to participate in ...
    (Date:2/22/2017)... ... February 22, 2017 , ... Alto-Shaam is pleased ... Series Multi-Cook Oven offers up to four ovens in one. Control temperature, fan ... for unmatched evenness in cooking. Alto-Shaam has partnered with Appliance Innovation to introduce ...
    (Date:2/21/2017)... ... ... Author Michèle Wolff has a passion for using food as medicine . ... it for optimal health. Wanting to share her knowledge to the world, she debuts ... ” (published by Balboa Press AU). , This book inspires readers to discover ...
    Breaking Medicine News(10 mins):